DOI: https://doi.org/10.53350/pjmhs2115113346

ORIGINAL ARTICLE

Role of Biochemical Markers in Detection of Myocardial Infarction

FAREEHA CHEEMA[1], ZAHID MAHMOOD[2], NASIR IQBAL[3], HASSAN JAMIL[4], SAIMA RUBAB KHAN[5], ANAS KHALIL[6]
[1]Demonstrator, Department of Biochemistry, Gujranwala Medical College
[2]Associate Professor, Department of Biochemistry, Wah Medical College, National University of Medical Sciences Rawalpindi
[3]Associate Professor, Department of Cardiology, Azra Naheed Medical College, Superior University Lahore
[4]Associate Professor, Department of Biochemistry, Sharif Medical and Dental College
[5]Associate Professor, Department of Biochemistry, Azra Naheed Dental College, Superior University Lahore
[6]Assistant Professor, Department of Biochemistry, Wah Medical College, National University of Medical Sciences Rawalpindi
Correspondence to Dr Fareeha Cheema, Email: dr.fareehacheema@yahoo.com, Cell: 0336-4867059

ABSTRACT

Introduction: Acute myocardial infarction causes significant mortality and morbidity. Timely conclusion permits clinicians to risk stratify their patients and select suitable treatment. Biomarkers have been utilized to help with timely decision, whereas an expanding number of novel markers have been recognized to predict result taking after an acute myocardial infarction or acute coronary disorder.
This may encourage tailoring of appropriate treatment to high-risk patients. This survey focuses on an assortment of promising biomarkers which give symptomatic and prognostic data.
Objective: To compare the early demonstrative efficiency of the cardiac troponin I (cTn-I) level with that of the cardiac troponin T (cTn-T) level, as well as the creatine kinase (CK), CK-MB, and myoglobin levels, for acute myocardial infarction (AMI) in patients without an initially diagnostic ECG presenting to the Emergency department within 24 hours of the onset of their symptoms.
Material and Methods
Study design: Prospective Observational Cohort
Settings: Punjab Institute of Cardiology
Duration: Six months i.e. 1st January 2020 to 30th June 2020
Data Collection procedure: A planned, observational, cohort study was performed including chest pain patients admitted to territory care hospital. Members were sequential consenting through Emergency department with chest pain and age more than 30 years. Exclusion included having symptoms >24 hours, failure to total information collection, receipt of CPR, and ST-segment elevation on the starting ECG. Estimations included levels of Trop-I, Trop- T, CK, CK-MB, and myoglobin at the time of introduction and 1, 2, 6, and 12-24 hours after presentation as well as showing ECG and clinical follow-up. The collected data was analyzed by using SPSS version 23.
Results: 140 included for study out of the 200 patients, 21 (14%) were analyzed as having acute myocardial infarction after diagnostic ECG testing. The sensitivities of all 5 biochemical markers for acute myocardial infarction were poor at the time of emergency department induction. The sensitivity of Trop-T was essentially superior to that of Trop-I over the starting 2 hours (3.2-33.1), but both markers' sensitivities were low (<60%) during this time outline. The Trop-I was significantly more particular for acute myocardial infarction than was the Trop-T, but not essentially better than CK-MB or myoglobin. Likelihood proportion analysis appeared that the biochemical markers with the most elevated positive ratios for acute myocardial infarction amid the primary 2 hours taking after emergency department admission were myoglobin and CK-MB. From 6 through 24 hours, the positive probability proportions for Trop I, CK-MB, and myoglobin were predominant to those of CK and Trop-T.
Conclusion: Trop-I, CK-MB, and myoglobin are essentially more particular for acute myocardial infarction than are CK and Trop-T. Myoglobin is the biochemical marker having the most elevated combination of sensitivity, specificity, and negative predictive value for acute myocardial infarction inside 2 hours of emergency department induction. Not one or the other Trop-I nor Trop-T offers significant advantages over myoglobin and CK-MB within the early less than 2 hours starting screening for acute myocardial infarction. The cardiac troponins are of advantage in recognizing acute myocardial infarction greater than 6 hours after presentation.
Key words: Myocardial Infarction, CKMB, Trop t, Trop I, Myoglobin

INTRODUCTION

Ischemic heart diseases like coronary artery disease leading to Myocardial infarction causes mortality and morbidity[1]. Timely diagnosis permits clinicians to take a chance on their patients and select suitable treatment plan. Biomarkers have been utilized to help with timely decision, whereas an expanding number of markers give prognosis about the heart diseases. This may encourage tailoring of appropriate treatment to high risk patients. This survey focuses on an assortment of promising biomarkers which give symptomatic and prognostic data[2].

The administration of patients presenting to the Emergency department with chest pain and breathing difficulty with possible diagnosis of acute myocardial infarction (AMI) speak to a troublesome issue for emergency doctors (EPs), in spite of the recurrence of introduction of these patients. The disposition of such patients has traditionally rested fundamentally on the patient's presenting history and the ECG[3].

In case the diagnosis of unstable ischemic heart illness cannot definitely be ruled out, the patient is traditionally admitted to rule out AMI utilizing serial serum markers.

As of now, creatine kinase (CK) and its isoenzyme, CK-MB, are acknowledged as the symptomatic reference standard for serum tests for intense myocardial infarction. However, the variable concentration of CK-MB in skeletal muscle, the failure of totals CK to rise to irregular levels in all intense myocardial localized necrosis. the variable "normal" serum levels of CK-MB, and the relatively brief term of CK and CK-MB height following may some of the time restrain the demonstrative utility of these values. Other biochemical markers, such as myoglobin, have been considered to help within the early biochemical discovery of acute myocardial infarction[4].

The use of serum levels of cardiac troponins I and T (Trop-I and Trop-T) have not, be that as it may, been well considered for the early detection of acute myocardial infarction. The isoforms of Trop-T and Trop-I in skeletal muscle have significantly different protein structures from those in cardiac muscle, allowing essentially total separation of cardiac vs skeletal muscle damage[5].

These markers reportedly rise to anomalous concentrations 4-8 hours after myocardial damage and stay raised 7-10 days, coming about in a longer "diagnostic window" than right now used biochemical markers[6, 7].

MATERIAL AND METHODS

A planned, observational, cohort study was performed including chest pain patients admitted to territory care hospital. Members were sequential consenting through Emergency department with chest pain and age more than 30 years. Exclusion included having symptoms >24 hours, failure to total information collection, receipt of CPR, and ST-segment elevation on the starting ECG. Estimations included levels of Trop-I, Trop- T, CK, CK-MB, and myoglobin at the time of introduction and 1, 2, 6, and 12-24 hours after presentation as well as showing ECG and clinical follow-up. The collected data was analyzed by using SPSS version 23.

RESULTS

140 included for study out of the 200 patients, 21 (14%) were analyzed as having acute myocardial infarction after diagnostic ECG testing. The sensitivities of all 5 biochemical markers for acute myocardial infarction were poor at the time of emergency department induction. The sensitivity of Trop-T was essentially superior to that of Trop-I over the starting 2 hours (3.2-33.1), but both markers' sensitivities were low (<60%) during this time outline. The Trop-I was significantly more particular for acute myocardial infarction than was the Trop-T, but not essentially better than CK-MB or myoglobin. Likelihood proportion analysis appeared that the biochemical markers with the most elevated positive ratios for acute myocardial infarction amid the primary 2 hours taking after emergency department admission were myoglobin and CK-MB. From 6 through 24 hours, the positive probability proportions for Trop I, CK-MB, and myoglobin were predominant to those of CK and Trop-T.

Table 1: Inclusion & Exclusion criteria for patient testing

Total Patients		200
Exclusion	Left against medical advice	05
	Discharge after minor treatment	15
	Symptoms more than 24 hours	20
	Transferred to other department	10
	Not signed for treatment	10
Excluded total		60
Included for study		140

Table 2: Sensitivity & Specificity of Biochemical Markers

	Sensitivity					Specificity				
	T_o	T_1	T_2	T_6	T_{12-24}	T_o	T_1	T_2	T_6	T_{12-24}
Myoglobin ng/mL	32	72	86	80.3	57.2	90	90	94.2	94.2	93.5
Total Ck U/L	28.2	28.4	32.4	80.2	80.3	82.2	83.4	84	86.2	87.8
CK-MB ng/mL	26	42.3	50.2	99	100	96.2	94.5	97.2	98	98.2
Trop I ng/mL	3.2	7.1	21.1	80	87.5	97	98	98	98	99
Trop T ng/mL	32.1	32.3	57.6	87.2	95.3	87.4	87.5	86	86.2	87

Sensitivity & Specificity of Biochemical Markers at the time of admission (To), 1 (T1), 2 (T2), 6 (T6), 12-24 (T12-24)

Table 3: Negative & Positive Predictive Value of Biochemical Markers

	Negative Predictive Value					Positive Predictive Value				
	T_o	T_1	T_2	T_6	T_{12-24}	T_o	T_1	T_2	T_6	T_{12-24}
Myoglobin ng/mL	87.2	94	97.3	97	94	41	60.5	78.2	80.4	70.5
Total Ck U/L	86.3	85.3	87.5	94.2	95.6	23	24	25.6	52.3	55.8
CK-MB ng/mL	86.3	88	90.5	99	100	56	78	67.5	78.2	85.8
Trop I ng/mL	85.2	84.9	86.9	94.8	98.2	30	40.2	65.2	88.6	90.2
Trop T ng/mL	88.9	86.5	89.3	96.5	98.9	33.2	33.2	46.8	52.8	59.3

Negative & Positive Predictive value of Biochemical Markers at the time of admission (To), 1 (T1), 2 (T2), 6 (T6), 12-24 (T12-24)

DISCUSSION

For conceded patients, serial checking of cardiac markers is standard hone to run the show in or out acute myocardial infarction. The potential use of these markers within the emergency division time outlines calls for an understanding of their characteristics and energy by the doctor. Trop-I and Trop-T are hereditarily particular from skeletal muscle troponins such that any serum rise of these markers is particular for myocardial injury[8]. The specificities of Trop-I and Trop-T speak to an obvious advantage over CK, CK-MB, myoglobin in clarifying the diagnosis of acute myocardial infarction in patients with uninterruptable comes about of the last mentioned markers or in patients with concomitant skeletal muscle injury or pathology. We have prospectively compared the test exhibitions of Trop-I and Trop-T, myoglobin, CK, and CK-MB for acute myocardial dead tissue in patients conceded to the hospital after

displaying to the emergency department inside 24 hours of the onset of indications[9, 10].

CONCLUSION

Trop-I, CK-MB, and myoglobin are essentially more particular for acute myocardial infarction than are CK and Trop-T. Myoglobin is the biochemical marker having the most elevated combination of sensitivity, specificity, and negative predictive value for acute myocardial infarction inside 2 hours of emergency department induction. Not one or the other Trop-I nor Trop-T offers significant advantages over myoglobin and CK-MB within the early less than 2 hours starting screening for acute myocardial infarction. The cardiac troponins are of advantage in recognizing acute myocardial infarction greater than 6 hours after presentation.

In spite of the fact that there are huge numbers of developing novel biomarkers, our understanding of the parts and organic chemistry of these different peptides within the disease prepare is still decently restricted. It is troublesome to draw particular conclusions from the current body of prove with respect to the instruments through which a biomarker might influence the prognosis. Numerous of the studies use passing or major adverse cardiovascular occasions as conclusion points since they are simple to degree, but either of these endpoints may be a culmination of a assortment of pathophysiological forms. As such, right now accessible biomarkers have not been able to include much to helping us tailors our treatment (over and over Troponin). Randomized trials based on the use of biomarkers to modify treatment would be exceptionally enlightening.

Limitations & Future Concerns

Our study was restricted by the relatively small sample size for our study population. A bigger, multicenter study would include to the generalizability of the information and might also offer assistance maintain a strategic distance from lost more unpretentious contrasts between these markers. Only admitted patients were included in our study population. This improved our capacity to gather more complete information from those included. Furthermore, the study's reason was to track the symptomatic utility of these markers for acute myocardial infarction and was not tentatively planned to act on these values for triage purposes.

In any case, the study did avoid a significant subset of patients for whom these results may have particular importance, i.e., patients assessed within the emergency department for chest pain who are subsequently released to home

REFERNCES

1. White HD, Chew DP. Acute myocardial infarction. The Lancet. 2008;372(9638):570-84.
2. Boersma E, Mercado N, Poldermans D, Gardien M, Vos J, Simoons ML. Acute myocardial infarction. The Lancet. 2003;361(9360):847-58.
3. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. European heart journal. 2003;24(1):28-66.
4. Sharif Nia H, Gorgulu O, Naghavi N, Froelicher ES, Fomani FK, Goudarzian AH, et al. A time-series prediction model of acute myocardial infarction in northern of Iran: the risk of climate change and religious mourning. BMC Cardiovascular Disorders. 2021;21(1):1-11.
5. Aydin S, Ugur K, Sahin İ, Yardim M, Aydin S, Ugur K, et al. Biomarkers in acute myocardial infarction: current perspectives| VHRM.
6. Chiang C-H, Chiang C-H, Pickering JW, Stoyanov KM, Chew DP, Neumann JT, et al. Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction: An International Collaborative Meta-analysis. Annals of Internal Medicine. 2021.
7. Schneider U, Mukharyamov M, Beyersdorf F, Dewald O, Liebold A, Gaudino M, et al. The value of perioperative biomarker release for the assessment of myocardial injury or infarction in cardiac surgery. European Journal of Cardio-Thoracic Surgery. 2021.
8. Sinha S, Benedetto U, Mulla A, Glampson B, Panoulas VF, Gautama S, et al. Implications of Elevated Troponin on Time-to-Surgery in Non-ST Elevation Myocardial Infarction (NIHR Health Informatics Collaborative: Trop-CABG Study). Circulation. 2021;144(Suppl_1):A14169-A.
9. Singleton MJ, German CA, Soliman EZ, Burke GL, Yeboah J. Association of Silent Myocardial Infarction on Electrocardiogram and Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis. Circulation. 2021;144(Suppl_1):A9305-A.
10. Hayek A, Derimay F, Bochaton T. Biomarkers for Myocardial Infarction Type Discrimination—The Key Might Be in the Time Course of the Disease. JAMA cardiology. 2021.